Your platform is differentiated and your team knows exactly why. The investors, partners, and boards who decide your future do not yet.
The gap is not in the science. It is in how the value is articulated. Left unmanaged, that gap costs rounds, partnerships, and time.
Closing it is a discipline of its own, one we call science value articulation.
A science value proposition (SVP) articulates how a company's science translates into new capabilities and real-world impact.
At its core it answers the two questions that matter most to stakeholders: What is the key discovery? Why does it matter? The SVP becomes the foundation for a coherent narrative that resonates with investors, partners, and the scientific community.
The scientific insight that makes everything else possible: a novel target, proprietary assay, delivery breakthrough, or an algorithm that reads biology in a new way. Its potential matters more than its nature. A discovery that opens a therapeutic window gives a concrete reason to believe.
How the discovery stands apart — superior performance, novel insight, or data others cannot easily replicate. That differentiation converts interesting science into a defensible position.
A well-defined discovery drives indication priority, partnerships, and resource allocation. Grounded in the SVP, every decision reinforces one coherent narrative about why the company wins.
The full SVP — discovery, innovation, and the strategy it shapes — articulated as the defensible foundation everything else draws from.
Case note: Dispatch Bio →The TVP and CLVP that carry the insight into development and the clinic.
Case note: aTyr Efzofitimod →The structural story of a platform that has to scale across programs.
Case note: Pacira PCRX-201 →Where the asset sits, why it matters now, and how the pipeline reads as one argument.
Case note: eGenesis →The scientific story carried consistently into how the company presents itself.
The earliest version of the story, shaped for the first rooms that fund it.
A root-cause approach to retinal disease: clear the lipid that drives it. Carried by a platform, not a single drug.
A novel modality in a field trained on familiar mechanisms and single assets. The science was sound; what it lacked was a through-line an investor could hold.
One scientific value proposition, built once and carried across the platform and the raise, with a visual system that made an invisible mechanism impossible to miss.
The discipline of translating a scientific platform, asset, or pipeline into a clear, defensible value narrative that the audiences who fund and advance it can understand and believe.
An SVP articulates how a company's science translates into new capabilities and real-world impact, answering the two questions that matter most: what is the key discovery, and why does it matter?
The SVP captures the core scientific insight; the TVP, how it becomes a repeatable technology capability; the CLVP, how it becomes patient impact. Together they form one connected narrative from discovery to clinic.
By grounding everything in an SVP — a key discovery, a unique innovation, and the strategy it shapes — so every decision reinforces one coherent narrative about why the company wins.
A pitch deck is a document; an SVP is the underlying argument. The SVP is the defensible value narrative the deck, the data room, and the team all draw from.